TG Therapeutics Files Definitive Proxy, Reveals Low 54.3% Say-on-Pay Approval for 2025 Executive Compensation
Summary
TG Therapeutics filed its definitive proxy statement, revealing that its 2025 executive compensation received only 54.3% shareholder approval, prompting a review of compensation practices.
Key Events
-
Annual Meeting Scheduled
The company will hold its virtual Annual Meeting of Stockholders on June 11, 2026, to elect six directors, ratify KPMG LLP as its independent auditor, and conduct an advisory vote on executive compensation.
-
Low Say-on-Pay Approval
The 2025 advisory vote on executive officer compensation received only 54.3% shareholder approval, signaling notable investor concern regarding the company's executive pay practices.
-
Executive Compensation Review Initiated
In response to the 2025 say-on-pay vote, the Compensation Committee engaged a new independent compensation consultant, Compensia, to review and align its executive compensation program with market practices and shareholder interests.
-
2025 Executive Compensation Details
CEO Michael S. Weiss received $25.57 million in total compensation for 2025, including a $23.55 million performance-based restricted stock award. CFO Sean A. Power received $3.77 million, including a $2.92 million time-based restricted stock award.
Analysis
This definitive proxy statement outlines the agenda for the upcoming annual meeting, including the election of directors, auditor ratification, and an advisory vote on executive compensation. A key highlight is the disclosure that the 2025 "Say-on-Pay" proposal received only 54.3% shareholder approval, indicating significant shareholder dissatisfaction with executive compensation practices. In response, the Compensation Committee engaged a new independent compensation consultant to review its program. Investors should monitor the upcoming annual meeting and any subsequent changes to compensation policies.
At the time of this filing, TGTX was trading at $33.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $25.28 to $46.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.